Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Infectious Disease

PUBLISHER: Persistence Market Research | PRODUCT CODE: 1457355

Cover Image

PUBLISHER: Persistence Market Research | PRODUCT CODE: 1457355

Onychomycosis Treatment Market by Product Type, End-Users, and Geography (North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa): Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2030

PUBLISHED:
PAGES: 234 Pages
DELIVERY TIME: 2-5 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
Unprintable PDF & Excel (Single User License)
USD 4995
PDF & Excel (Multi User License)
USD 7295
PDF & Excel (Corporate User License)
USD 8495

Add to Cart

Description

Table of Contents

Persistence Market Research presents a comprehensive report on the global Onychomycosis Treatment Market, highlighting its substantial growth potential driven by the increasing prevalence of fungal nail infections and the rising demand for effective treatment options. Onychomycosis, a common fungal infection of the nails, poses significant clinical and aesthetic concerns, leading to a growing burden on healthcare systems and impacting patients' quality of life. The report emphasizes the critical need for innovative and efficacious treatments to address this prevalent dermatological condition effectively.

The global onychomycosis treatment market is forecast to expand at a CAGR of 7.6% and thereby increase from a value of US$51 Bn in 2023, to US$85.1 Bn by the end of 2030.

Key Insights

Onychomycosis Treatment Market Size (2023E): US$51 billion

Projected Market Value (2030F): US$85.1 billion

Global Market Growth Rate (CAGR 2023 to 2030): 7.6%

Historical Market Growth Rate (CAGR 2018 to 2022): 4.9%

Onychomycosis Treatment Market - Report Scope

The Onychomycosis Treatment Market report provides a comprehensive analysis of market dynamics, including drivers, restraints, opportunities, and challenges shaping the industry landscape. Onychomycosis, characterized by nail discoloration, thickening, and deformity, is predominantly caused by dermatophyte fungi, presenting diagnostic and therapeutic challenges for healthcare providers. The report delves into the nuances of onychomycosis treatment, examining factors influencing market growth, competitive landscape, and emerging trends driving innovation in antifungal therapies.

Market Growth Drivers for Onychomycosis Treatment Market:

The increasing prevalence of onychomycosis, attributed to factors such as aging demographics, diabetes mellitus, immunosuppression, and poor foot hygiene, is a primary driver for the onychomycosis treatment market. Elderly individuals and patients with underlying medical conditions are particularly susceptible to fungal nail infections due to compromised immune function, reduced peripheral circulation, and structural nail changes, necessitating timely diagnosis and treatment interventions.

Furthermore, the growing awareness about the clinical consequences and psychosocial impact of onychomycosis, including pain, discomfort, embarrassment, and impaired quality of life, is driving patient and physician demand for effective treatment options. Onychomycosis treatment aims to eradicate fungal pathogens, restore nail health, and prevent disease recurrence, offering symptomatic relief and cosmetic improvement for affected individuals.

Technological advancements in antifungal therapies, including the development of novel topical formulations, oral medications, and medical devices for nail debridement and laser therapy, are enhancing treatment outcomes, patient compliance, and therapeutic efficacy. Manufacturers are investing in research and development to innovate drug delivery systems, enhance antifungal potency, and optimize treatment regimens, aiming to address the evolving clinical needs and preferences of healthcare providers and patients.

Market Restraints

Despite the promising market outlook, the onychomycosis treatment market faces challenges related to treatment resistance, safety concerns, and regulatory barriers. Fungal nail infections can be challenging to treat due to the slow growth rate of nails, the presence of subungual debris, and the development of antifungal resistance, necessitating prolonged and multifaceted treatment approaches.

Moreover, systemic antifungal medications, such as oral azoles and allylamines, may be associated with adverse effects, drug interactions, and hepatotoxicity, limiting their utility in certain patient populations, including elderly individuals and those with liver impairment. Safety considerations, drug tolerability, and treatment adherence are crucial factors influencing treatment selection and patient outcomes in onychomycosis management.

Market Opportunities

Amidst the challenges lie opportunities for innovation, collaboration, and market expansion within the onychomycosis treatment market. Leveraging advancements in medical mycology, dermatopharmacology, and antifungal drug discovery can facilitate the development of next-generation therapies with improved efficacy, safety, and patient convenience.

Furthermore, fostering collaborations between pharmaceutical companies, academic institutions, and research organizations can accelerate drug development initiatives, preclinical studies, and clinical trials for novel antifungal agents and treatment modalities. By leveraging genomics, proteomics, and high-throughput screening technologies, researchers can identify new drug targets, repurpose existing medications, and optimize therapeutic regimens for onychomycosis.

Educational initiatives aimed at raising awareness about onychomycosis prevention, diagnosis, and treatment can empower healthcare providers and patients to adopt evidence-based practices and seek timely medical intervention. Patient education materials, clinical practice guidelines, and continuing medical education programs play a crucial role in improving diagnostic accuracy, treatment adherence, and long-term clinical outcomes in onychomycosis management.

Key Questions Answered in Report::

  • What is the Forecast CAGR of the Onychomycosis Treatment Market in 2030?
  • What is the Global Market Size of Onychomycosis Treatment as of the End of 2023?
  • Which Region Dominated the Onychomycosis Treatment Market in 2023?
  • Who are the Key Players in the Global Onychomycosis Treatment Market?
  • Which Onychomycosis Treatment Segments Hold the Largest Opportunities for Market Integration?

Competitive Intelligence and Business Strategy

In navigating the competitive landscape, companies in the Onychomycosis Treatment Market must leverage competitive intelligence and strategic business initiatives to differentiate themselves and capitalize on emerging opportunities. Understanding market dynamics, customer preferences, and competitor strategies is essential for informed decision-making and market positioning.

Furthermore, investing in research and development, clinical trials, and regulatory compliance can help companies bring innovative therapies to market, gain regulatory approval, and expand market share. By focusing on patient-centric approaches, physician education, and market access strategies, companies can enhance product adoption, drive revenue growth, and improve patient outcomes in the dynamic Onychomycosis Treatment Market.

Key Companies Profiled

  • Teva Pharmaceutical Industries Ltd.
  • Sanofi S.A.
  • Medimetriks Pharmaceuticals, Inc.
  • Galderma
  • Johnson & Johnson
  • Novartis AG
  • Moberg Pharma AB
  • Cardinal Health, Inc.
  • Pfizer Inc.
  • Almirall, S.A.
  • Bayer AG
  • Viatris Inc.
  • GlaxoSmithKline plc
  • Cipla Ltd.
  • Dr. Reddy's Laboratories Ltd

Onychomycosis Treatment Market Research Segmentation

Market segmentation based on drug class, route of administration, distribution channel, and region provides valuable insights into key market segments and regional dynamics, enabling companies to tailor their offerings to specific customer needs and preferences. By understanding the unique requirements of different patient populations and geographic markets, companies can develop targeted strategies to address market demands effectively, thereby gaining a competitive edge and driving growth in the Onychomycosis Treatment Market.

Onychomycosis Treatment Market Research Segmentation

By Treatment Type:

  • Drugs
  • Oral
  • Rx
  • OTC
  • Topical
  • Rx
  • OTC
  • Lasers
  • C02 Ablative Lasers
  • Nd: YAG Lasers
  • Dual-wavelength near-infrared Lasers
  • Photodynamic Therapy

By Disease Indication:

  • Distal Subungual Onychomycosis
  • White Superficial Onychomycosis
  • Proximal Subungual Onychomycosis
  • Candidal Onychomycosis
  • Total Dystrophic Onychomycosis

By Age Group:

  • 0 to 18 Years
  • 18 to 39 Years
  • 40 to 64 Years
  • 65 Years & Above

By Distribution Channel:

  • Institutional Sales
  • Hospitals
  • Dermatology Clinics
  • Retail Sales
  • Retail Pharmacies
  • Drug Stores
  • Mail Order Pharmacies & Online Sales

By Region:

  • North America
  • Europe
  • East Asia
  • South Asia & Oceania
  • Latin America
  • Middle East & Africa
Show more
Product Code: PMRREP34004

Table of Contents

1. Executive Summary

  • 1.1. Global Onychomycosis Treatment Market Snapshot, 2023 and 2030
  • 1.2. Market Opportunity Assessment, 2023 - 2030, US$ Mn
  • 1.3. Key Market Trends
  • 1.4. Future Market Projections
  • 1.5. Premium Market Insights
  • 1.6. Industry Developments and Key Market Events
  • 1.7. PMR Analysis and Recommendations

2. Market Overview

  • 2.1. Market Scope and Definition
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Opportunity
    • 2.2.4. Challenges
    • 2.2.5. Key Trends
  • 2.3. Treatment Type Lifecycle Analysis
  • 2.4. Onychomycosis Treatment Market: Value Chain
    • 2.4.1. List of Raw Material Supplier
    • 2.4.2. List of Manufacturers
    • 2.4.3. List of Distributors
    • 2.4.4. List of Applications
    • 2.4.5. Profitability Analysis
  • 2.5. Porter Five Force's Analysis
  • 2.6. Geopolitical Tensions: Market Impact
  • 2.7. Macro-Economic Factors
    • 2.7.1. Global Sectorial Outlook
    • 2.7.2. Global GDP Growth Outlook
    • 2.7.3. Global Parent Market Overview
  • 2.8. Forecast Factors - Relevance and Impact
  • 2.9. Regulatory and Technology Landscape

3. Global Onychomycosis Treatment Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)

  • 3.1. Key Highlights
    • 3.1.1. Market Volume (Units) Projections
    • 3.1.2. Market Size and Y-o-Y Growth
    • 3.1.3. Absolute $ Opportunity
  • 3.2. Market Size (US$ Mn) Analysis and Forecast
    • 3.2.1. Historical Market Size Analysis, 2013-2016
    • 3.2.2. Current Market Size Forecast, 2018-2026
  • 3.3. Global Onychomycosis Treatment Market Outlook: Treatment Type
    • 3.3.1. Introduction / Key Findings
    • 3.3.2. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Treatment Type, 2018 - 2022
    • 3.3.3. Current Market Size (US$ Mn) and Volume (Units) Forecast By Treatment Type, 2023 - 2030
      • 3.3.3.1. Drugs
        • 3.3.3.1.1. Oral
        • 3.3.3.1.2. Rx
        • 3.3.3.1.3. OTC
        • 3.3.3.1.4. Topical
        • 3.3.3.1.5. Rx
        • 3.3.3.1.6. OTC
      • 3.3.3.2. Lasers
        • 3.3.3.2.1. C02 Ablative Lasers
        • 3.3.3.2.2. Nd: YAG Lasers
        • 3.3.3.2.3. Dual-wavelength near-infrared Lasers
      • 3.3.3.3. Photodynamic Therapy
  • 3.4. Market Attractiveness Analysis: Treatment Type
  • 3.5. Global Onychomycosis Treatment Market Outlook: Disease Indication
    • 3.5.1. Introduction / Key Findings
    • 3.5.2. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Disease Indication, 2018 - 2022
    • 3.5.3. Current Market Size (US$ Mn) and Volume (Units) Forecast By Disease Indication, 2023 - 2030
      • 3.5.3.1. Distal Subungual Onychomycosis
      • 3.5.3.2. White Superficial Onychomycosis
      • 3.5.3.3. Proximal Subungual Onychomycosis
      • 3.5.3.4. Candidal Onychomycosis
      • 3.5.3.5. Total Dystrophic Onychomycosis
  • 3.6. Market Attractiveness Analysis: Disease Indication
  • 3.7. Global Onychomycosis Treatment Market Outlook: Age Group
    • 3.7.1. Introduction / Key Findings
    • 3.7.2. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Age Group, 2018 - 2022
    • 3.7.3. Current Market Size (US$ Mn) and Volume (Units) Forecast By Age Group, 2023 - 2030
      • 3.7.3.1. 0 to 18 Years
      • 3.7.3.2. 18 to 39 Years
      • 3.7.3.3. 40 to 64 Years
      • 3.7.3.4. 65 Years & Above
  • 3.8. Market Attractiveness Analysis: Age Group
  • 3.9. Global Onychomycosis Treatment Market Outlook: Distribution Channel
    • 3.9.1. Introduction / Key Findings
    • 3.9.2. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Distribution Channel, 2018 - 2022
    • 3.9.3. Current Market Size (US$ Mn) and Volume (Units) Forecast By Distribution Channel, 2023 - 2030
      • 3.9.3.1. Institutional Sales
      • 3.9.3.2. Hospitals
      • 3.9.3.3. Dermatology Clinics
      • 3.9.3.4. Retail Sales
      • 3.9.3.5. Retail Pharmacies
      • 3.9.3.6. Drug Stores
      • 3.9.3.7. Mail Order Pharmacies & Online Sales
  • 3.10. Market Attractiveness Analysis: Distribution Channel

4. Global Onychomycosis Treatment Market Outlook: Region

  • 4.1. Key Highlights
  • 4.2. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Region, 2018 - 2022
  • 4.3. Current Market Size (US$ Mn) and Volume (Units) Forecast By Region, 2023 - 2030
    • 4.3.1. North America
    • 4.3.2. Europe
    • 4.3.3. East Asia
    • 4.3.4. South Asia and Oceania
    • 4.3.5. Latin America
    • 4.3.6. Middle East & Africa (MEA)
  • 4.4. Market Attractiveness Analysis: Region

5. North America Onychomycosis Treatment Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)

  • 5.1. Key Highlights
  • 5.2. Pricing Analysis
  • 5.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2018 - 2022
    • 5.3.1. By Country
    • 5.3.2. By Treatment Type
    • 5.3.3. By Disease Indication
    • 5.3.4. By Age Group
    • 5.3.5. By Distribution Channel
  • 5.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2023 - 2030
    • 5.4.1. U.S.
    • 5.4.2. Canada
  • 5.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Treatment Type, 2023 - 2030
    • 5.5.1. Drugs
      • 5.5.1.1. Oral
      • 5.5.1.2. Rx
      • 5.5.1.3. OTC
      • 5.5.1.4. Topical
      • 5.5.1.5. Rx
      • 5.5.1.6. OTC
    • 5.5.2. Lasers
      • 5.5.2.1. C02 Ablative Lasers
      • 5.5.2.2. Nd: YAG Lasers
      • 5.5.2.3. Dual-wavelength near-infrared Lasers
    • 5.5.3. Photodynamic Therapy
  • 5.6. Current Market Size (US$ Mn) and Volume (Units) Forecast By Disease Indication, 2023 - 2030
    • 5.6.1. Distal Subungual Onychomycosis
    • 5.6.2. White Superficial Onychomycosis
    • 5.6.3. Proximal Subungual Onychomycosis
    • 5.6.4. Candidal Onychomycosis
    • 5.6.5. Total Dystrophic Onychomycosis
  • 5.7. Current Market Size (US$ Mn) and Volume (Units) Forecast By Age Group, 2023 - 2030
    • 5.7.1. 0 to 18 Years
    • 5.7.2. 18 to 39 Years
    • 5.7.3. 40 to 64 Years
    • 5.7.4. 65 Years & Above
  • 5.8. Current Market Size (US$ Mn) and Volume (Units) Forecast By Distribution Channel, 2023 - 2030
    • 5.8.1. Institutional Sales
    • 5.8.2. Hospitals
    • 5.8.3. Dermatology Clinics
    • 5.8.4. Retail Sales
    • 5.8.5. Retail Pharmacies
    • 5.8.6. Drug Stores
    • 5.8.7. Mail Order Pharmacies & Online Sales
  • 5.9. Market Attractiveness Analysis

6. Europe Onychomycosis Treatment Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)

  • 6.1. Key Highlights
  • 6.2. Pricing Analysis
  • 6.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2018 - 2022
    • 6.3.1. By Country
    • 6.3.2. By Treatment Type
    • 6.3.3. By Disease Indication
    • 6.3.4. By Age Group
    • 6.3.5. By Distribution Channel
  • 6.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2023 - 2030
    • 6.4.1. Germany
    • 6.4.2. France
    • 6.4.3. U.K.
    • 6.4.4. Italy
    • 6.4.5. Spain
    • 6.4.6. Russia
    • 6.4.7. Turkiye
    • 6.4.8. Rest of Europe
  • 6.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Treatment Type, 2023 - 2030
    • 6.5.1. Drugs
      • 6.5.1.1. Oral
      • 6.5.1.2. Rx
      • 6.5.1.3. OTC
      • 6.5.1.4. Topical
      • 6.5.1.5. Rx
      • 6.5.1.6. OTC
    • 6.5.2. Lasers
      • 6.5.2.1. C02 Ablative Lasers
      • 6.5.2.2. Nd: YAG Lasers
      • 6.5.2.3. Dual-wavelength near-infrared Lasers
    • 6.5.3. Photodynamic Therapy
  • 6.6. Current Market Size (US$ Mn) and Volume (Units) Forecast By Disease Indication, 2023 - 2030
    • 6.6.1. Distal Subungual Onychomycosis
    • 6.6.2. White Superficial Onychomycosis
    • 6.6.3. Proximal Subungual Onychomycosis
    • 6.6.4. Candidal Onychomycosis
    • 6.6.5. Total Dystrophic Onychomycosis
  • 6.7. Current Market Size (US$ Mn) and Volume (Units) Forecast By Age Group, 2023 - 2030
    • 6.7.1. 0 to 18 Years
    • 6.7.2. 18 to 39 Years
    • 6.7.3. 40 to 64 Years
    • 6.7.4. 65 Years & Above
  • 6.8. Current Market Size (US$ Mn) and Volume (Units) Forecast By Distribution Channel, 2023 - 2030
    • 6.8.1. Institutional Sales
    • 6.8.2. Hospitals
    • 6.8.3. Dermatology Clinics
    • 6.8.4. Retail Sales
    • 6.8.5. Retail Pharmacies
    • 6.8.6. Drug Stores
    • 6.8.7. Mail Order Pharmacies & Online Sales
  • 6.9. Market Attractiveness Analysis

7. East Asia Onychomycosis Treatment Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)

  • 7.1. Key Highlights
  • 7.2. Pricing Analysis
  • 7.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2018 - 2022
    • 7.3.1. By Country
    • 7.3.2. By Treatment Type
    • 7.3.3. By Disease Indication
    • 7.3.4. By Age Group
    • 7.3.5. By Distribution Channel
  • 7.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2023 - 2030
    • 7.4.1. China
    • 7.4.2. Japan
    • 7.4.3. South Korea
  • 7.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Treatment Type, 2023 - 2030
    • 7.5.1. Drugs
      • 7.5.1.1. Oral
      • 7.5.1.2. Rx
      • 7.5.1.3. OTC
      • 7.5.1.4. Topical
      • 7.5.1.5. Rx
      • 7.5.1.6. OTC
    • 7.5.2. Lasers
      • 7.5.2.1. C02 Ablative Lasers
      • 7.5.2.2. Nd: YAG Lasers
      • 7.5.2.3. Dual-wavelength near-infrared Lasers
    • 7.5.3. Photodynamic Therapy
  • 7.6. Current Market Size (US$ Mn) and Volume (Units) Forecast By Disease Indication, 2023 - 2030
    • 7.6.1. Distal Subungual Onychomycosis
    • 7.6.2. White Superficial Onychomycosis
    • 7.6.3. Proximal Subungual Onychomycosis
    • 7.6.4. Candidal Onychomycosis
    • 7.6.5. Total Dystrophic Onychomycosis
  • 7.7. Current Market Size (US$ Mn) and Volume (Units) Forecast By Age Group, 2023 - 2030
    • 7.7.1. 0 to 18 Years
    • 7.7.2. 18 to 39 Years
    • 7.7.3. 40 to 64 Years
    • 7.7.4. 65 Years & Above
  • 7.8. Current Market Size (US$ Mn) and Volume (Units) Forecast By Distribution Channel, 2023 - 2030
    • 7.8.1. Institutional Sales
    • 7.8.2. Hospitals
    • 7.8.3. Dermatology Clinics
    • 7.8.4. Retail Sales
    • 7.8.5. Retail Pharmacies
    • 7.8.6. Drug Stores
    • 7.8.7. Mail Order Pharmacies & Online Sales
  • 7.9. Market Attractiveness Analysis

8. South Asia & Oceania Onychomycosis Treatment Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)

  • 8.1. Key Highlights
  • 8.2. Pricing Analysis
  • 8.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2018 - 2022
    • 8.3.1. By Country
    • 8.3.2. By Treatment Type
    • 8.3.3. By Disease Indication
    • 8.3.4. By Age Group
    • 8.3.5. By Distribution Channel
  • 8.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2023 - 2030
    • 8.4.1. India
    • 8.4.2. Southeast Asia
    • 8.4.3. ANZ
    • 8.4.4. Rest of South Asia & Oceania
  • 8.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Treatment Type, 2023 - 2030
    • 8.5.1. Drugs
      • 8.5.1.1. Oral
      • 8.5.1.2. Rx
      • 8.5.1.3. OTC
      • 8.5.1.4. Topical
      • 8.5.1.5. Rx
      • 8.5.1.6. OTC
    • 8.5.2. Lasers
      • 8.5.2.1. C02 Ablative Lasers
      • 8.5.2.2. Nd: YAG Lasers
      • 8.5.2.3. Dual-wavelength near-infrared Lasers
    • 8.5.3. Photodynamic Therapy
  • 8.6. Current Market Size (US$ Mn) and Volume (Units) Forecast By Disease Indication, 2023 - 2030
    • 8.6.1. Distal Subungual Onychomycosis
    • 8.6.2. White Superficial Onychomycosis
    • 8.6.3. Proximal Subungual Onychomycosis
    • 8.6.4. Candidal Onychomycosis
    • 8.6.5. Total Dystrophic Onychomycosis
  • 8.7. Current Market Size (US$ Mn) and Volume (Units) Forecast By Age Group, 2023 - 2030
    • 8.7.1. 0 to 18 Years
    • 8.7.2. 18 to 39 Years
    • 8.7.3. 40 to 64 Years
    • 8.7.4. 65 Years & Above
  • 8.8. Current Market Size (US$ Mn) and Volume (Units) Forecast By Distribution Channel, 2023 - 2030
    • 8.8.1. Institutional Sales
    • 8.8.2. Hospitals
    • 8.8.3. Dermatology Clinics
    • 8.8.4. Retail Sales
    • 8.8.5. Retail Pharmacies
    • 8.8.6. Drug Stores
    • 8.8.7. Mail Order Pharmacies & Online Sales
  • 8.9. Market Attractiveness Analysis

9. Latin America Onychomycosis Treatment Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)

  • 9.1. Key Highlights
  • 9.2. Pricing Analysis
  • 9.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2018 - 2022
    • 9.3.1. By Country
    • 9.3.2. By Treatment Type
    • 9.3.3. By Disease Indication
    • 9.3.4. By Age Group
    • 9.3.5. By Distribution Channel
  • 9.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2023 - 2030
    • 9.4.1. Brazil
    • 9.4.2. Mexico
    • 9.4.3. Rest of Latin America
  • 9.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Treatment Type, 2023 - 2030
    • 9.5.1. Drugs
      • 9.5.1.1. Oral
      • 9.5.1.2. Rx
      • 9.5.1.3. OTC
      • 9.5.1.4. Topical
      • 9.5.1.5. Rx
      • 9.5.1.6. OTC
    • 9.5.2. Lasers
      • 9.5.2.1. C02 Ablative Lasers
      • 9.5.2.2. Nd: YAG Lasers
      • 9.5.2.3. Dual-wavelength near-infrared Lasers
    • 9.5.3. Photodynamic Therapy
  • 9.6. Current Market Size (US$ Mn) and Volume (Units) Forecast By Disease Indication, 2023 - 2030
    • 9.6.1. Distal Subungual Onychomycosis
    • 9.6.2. White Superficial Onychomycosis
    • 9.6.3. Proximal Subungual Onychomycosis
    • 9.6.4. Candidal Onychomycosis
    • 9.6.5. Total Dystrophic Onychomycosis
  • 9.7. Current Market Size (US$ Mn) and Volume (Units) Forecast By Age Group, 2023 - 2030
    • 9.7.1. 0 to 18 Years
    • 9.7.2. 18 to 39 Years
    • 9.7.3. 40 to 64 Years
    • 9.7.4. 65 Years & Above
  • 9.8. Current Market Size (US$ Mn) and Volume (Units) Forecast By Distribution Channel, 2023 - 2030
    • 9.8.1. Institutional Sales
    • 9.8.2. Hospitals
    • 9.8.3. Dermatology Clinics
    • 9.8.4. Retail Sales
    • 9.8.5. Retail Pharmacies
    • 9.8.6. Drug Stores
    • 9.8.7. Mail Order Pharmacies & Online Sales
  • 9.9. Market Attractiveness Analysis

10. Middle East & Africa Onychomycosis Treatment Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)

  • 10.1. Key Highlights
  • 10.2. Pricing Analysis
  • 10.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2018 - 2022
    • 10.3.1. By Country
    • 10.3.2. By Treatment Type
    • 10.3.3. By Disease Indication
    • 10.3.4. By Age Group
    • 10.3.5. By Distribution Channel
  • 10.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2023 - 2030
    • 10.4.1. GCC
    • 10.4.2. Egypt
    • 10.4.3. South Africa
    • 10.4.4. Northern Africa
    • 10.4.5. Rest of Middle East & Africa
  • 10.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Treatment Type, 2023 - 2030
    • 10.5.1. Drugs
      • 10.5.1.1. Oral
      • 10.5.1.2. Rx
      • 10.5.1.3. OTC
      • 10.5.1.4. Topical
      • 10.5.1.5. Rx
      • 10.5.1.6. OTC
    • 10.5.2. Lasers
      • 10.5.2.1. C02 Ablative Lasers
      • 10.5.2.2. Nd: YAG Lasers
      • 10.5.2.3. Dual-wavelength near-infrared Lasers
    • 10.5.3. Photodynamic Therapy
  • 10.6. Current Market Size (US$ Mn) and Volume (Units) Forecast By Disease Indication, 2023 - 2030
    • 10.6.1. Distal Subungual Onychomycosis
    • 10.6.2. White Superficial Onychomycosis
    • 10.6.3. Proximal Subungual Onychomycosis
    • 10.6.4. Candidal Onychomycosis
    • 10.6.5. Total Dystrophic Onychomycosis
  • 10.7. Current Market Size (US$ Mn) and Volume (Units) Forecast By Age Group, 2023 - 2030
    • 10.7.1. 0 to 18 Years
    • 10.7.2. 18 to 39 Years
    • 10.7.3. 40 to 64 Years
    • 10.7.4. 65 Years & Above
  • 10.8. Current Market Size (US$ Mn) and Volume (Units) Forecast By Distribution Channel, 2023 - 2030
    • 10.8.1. Institutional Sales
    • 10.8.2. Hospitals
    • 10.8.3. Dermatology Clinics
    • 10.8.4. Retail Sales
    • 10.8.5. Retail Pharmacies
    • 10.8.6. Drug Stores
    • 10.8.7. Mail Order Pharmacies & Online Sales
  • 10.9. Market Attractiveness Analysis

11. Competition Landscape

  • 11.1. Market Share Analysis, 2022
  • 11.2. Market Structure
    • 11.2.1. Competition Intensity Mapping By Market
    • 11.2.2. Competition C02 Ablative Lasers
    • 11.2.3. Apparent Product Capacity
  • 11.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
    • 11.3.1. Teva Pharmaceutical Industries Ltd.
      • 11.3.1.1. Overview
      • 11.3.1.2. Segments and Product
      • 11.3.1.3. Key Financials
      • 11.3.1.4. Market Developments
      • 11.3.1.5. Market Strategy
    • 11.3.2. Sanofi S.A.
      • 11.3.2.1. Overview
      • 11.3.2.2. Segments and Product
      • 11.3.2.3. Key Financials
      • 11.3.2.4. Market Developments
      • 11.3.2.5. Market Strategy
    • 11.3.3. Medimetriks Pharmaceuticals, Inc.
      • 11.3.3.1. Overview
      • 11.3.3.2. Segments and Product
      • 11.3.3.3. Key Financials
      • 11.3.3.4. Market Developments
      • 11.3.3.5. Market Strategy
    • 11.3.4. Galderma
      • 11.3.4.1. Overview
      • 11.3.4.2. Segments and Product
      • 11.3.4.3. Key Financials
      • 11.3.4.4. Market Developments
      • 11.3.4.5. Market Strategy
    • 11.3.5. Johnson & Johnson
      • 11.3.5.1. Overview
      • 11.3.5.2. Segments and Product
      • 11.3.5.3. Key Financials
      • 11.3.5.4. Market Developments
      • 11.3.5.5. Market Strategy
    • 11.3.6. Novartis AG
      • 11.3.6.1. Overview
      • 11.3.6.2. Segments and Product
      • 11.3.6.3. Key Financials
      • 11.3.6.4. Market Developments
      • 11.3.6.5. Market Strategy
    • 11.3.7. Moberg Pharma AB
      • 11.3.7.1. Overview
      • 11.3.7.2. Segments and Product
      • 11.3.7.3. Key Financials
      • 11.3.7.4. Market Developments
      • 11.3.7.5. Market Strategy
    • 11.3.8. Cardinal Health, Inc.
      • 11.3.8.1. Overview
      • 11.3.8.2. Segments and Product
      • 11.3.8.3. Key Financials
      • 11.3.8.4. Market Developments
      • 11.3.8.5. Market Strategy
    • 11.3.9. Pfizer Inc.
      • 11.3.9.1. Overview
      • 11.3.9.2. Segments and Product
      • 11.3.9.3. Key Financials
      • 11.3.9.4. Market Developments
      • 11.3.9.5. Market Strategy
    • 11.3.10. Almirall, S.A.
      • 11.3.10.1. Overview
      • 11.3.10.2. Segments and Product
      • 11.3.10.3. Key Financials
      • 11.3.10.4. Market Developments
      • 11.3.10.5. Market Strategy
    • 11.3.11. Bayer AG
      • 11.3.11.1. Overview
      • 11.3.11.2. Segments and Product
      • 11.3.11.3. Key Financials
      • 11.3.11.4. Market Developments
      • 11.3.11.5. Market Strategy
    • 11.3.12. Viatris Inc.
      • 11.3.12.1. Overview
      • 11.3.12.2. Segments and Product
      • 11.3.12.3. Key Financials
      • 11.3.12.4. Market Developments
      • 11.3.12.5. Market Strategy
    • 11.3.13. GlaxoSmithKline plc
      • 11.3.13.1. Overview
      • 11.3.13.2. Segments and Product
      • 11.3.13.3. Key Financials
      • 11.3.13.4. Market Developments
      • 11.3.13.5. Market Strategy
    • 11.3.14. Cipla Ltd.
      • 11.3.14.1. Overview
      • 11.3.14.2. Segments and Product
      • 11.3.14.3. Key Financials
      • 11.3.14.4. Market Developments
      • 11.3.14.5. Market Strategy
    • 11.3.15. Dr. Reddy's Laboratories Ltd
      • 11.3.15.1. Overview
      • 11.3.15.2. Segments and Product
      • 11.3.15.3. Key Financials
      • 11.3.15.4. Market Developments
      • 11.3.15.5. Market Strategy

12. Appendix

  • 12.1. Research Methodology
  • 12.2. Research Assumptions
  • 12.3. Acronyms and Abbreviations
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!